In a report released today, Erin Wright from Morgan Stanley maintained a Sell rating on Walgreens Boots Alliance (WBA – Research Report), with a price target of $37.00. The company’s shares closed last Friday at $37.17.
Wright covers the Healthcare sector, focusing on stocks such as Cardinal Health, Cigna, and DENTSPLY SIRONA. According to TipRanks, Wright has an average return of 16.2% and a 64.82% success rate on recommended stocks.
Currently, the analyst consensus on Walgreens Boots Alliance is a Hold with an average price target of $42.63.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $48.72 and a one-year low of $30.04. Currently, Walgreens Boots Alliance has an average volume of 6.45M.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WBA in relation to earlier this year. Most recently, in November 2022, Ban Kevin M., the EVP, Chief Medical Officer of WBA sold 10,303.00 shares for a total of $414,077.57.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Retail pharmacy leader Walgreens Boots Alliance (NASDAQ:WBA) operates through its namesake brand Walgreens in the U.S. and Boots in the U.K. In addition, it owns retail and business brands including the No7 Beauty Company, Duane Reade, Ahumada in Chile, and Benavides in Mexico. The company also targets equity investments in healthcare, pharmacy, and retail and has a presence in over 25 countries with more than 450,000 employees.
Read More on WBA:
- WBA Looks to Sell Its Automation Unit
- Walgreens weighing sale of $2B pharmacy automation business, Bloomberg says
- Rite Aid plans to provide abortion pill in some stores, Bloomberg reports
- Walgreens Boots Alliance price target lowered to $42 from $44 at Truist
- Walgreens (NASDAQ:WBA) Settles Another Opioid-Related Case